The vast implications of B-51.

This modern series of breast cancers (n=57,531) demonstrates rates of axillary complete path response to neoadjuvant therapy is excellent, with an expected distribution across tumor subtypes: HER2+ (59%), triple-negative (48%), luminal B (35%), and luminal A (13%). | Samiei, JAMA Surg 2021